Home
/
ACADIA PHARMACEUTICALS INC
/
Financials
/
Quarterly
ACADIA PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ACADIA PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$48.87M
May 4, 2018
Q3
2017
Sep 30, 2017
$35.58M
Nov 7, 2017
Q2
2017
Jun 30, 2017
$30.48M
Aug 8, 2017
Q1
2018
Mar 31, 2017
$15.29M
May 4, 2018
Q3
2017
Sep 30, 2016
$5.27M
Nov 7, 2017
Q2
2017
Jun 30, 2016
$97.0K
Aug 8, 2017
Q1
2017
Mar 31, 2016
$4.0K
May 9, 2017
Q3
2016
Sep 30, 2015
$39.0K
Nov 7, 2016
Q2
2016
Jun 30, 2015
$1.0K
Aug 4, 2016
Q1
2016
Mar 31, 2015
$4.0K
May 5, 2016
Q3
2015
Sep 30, 2014
$15.0K
Nov 5, 2015
Q2
2015
Jun 30, 2014
$28.0K
Aug 6, 2015
Q1
2015
Mar 31, 2014
$30.0K
May 7, 2015
Q3
2014
Sep 30, 2013
$240.0K
Nov 10, 2014
Q2
2014
Jun 30, 2013
$451.0K
Aug 5, 2014
Q1
2014
Mar 31, 2013
$417.0K
May 6, 2014
Q3
2013
Sep 30, 2012
$3.48M
Nov 6, 2013
Q2
2013
Jun 30, 2012
$599.0K
Aug 6, 2013
Q1
2013
Mar 31, 2012
$450.0K
May 7, 2013
Q3
2012
Sep 30, 2011
$584.0K
Nov 5, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$278.63M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$264.57M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$244.32M
May 8, 2025
Q3
2025
Sep 30, 2024
$250.40M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$241.96M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$205.83M
May 8, 2025
Q3
2024
Sep 30, 2023
$211.70M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$165.24M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$118.46M
May 9, 2024
Q3
2023
Sep 30, 2022
$130.71M
Nov 3, 2023
Q2
2023
Jun 30, 2022
$134.56M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$115.47M
May 8, 2023
Q3
2022
Sep 30, 2021
$131.61M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$115.22M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$106.55M
May 5, 2022
Q3
2021
Sep 30, 2020
$120.58M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$110.10M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$90.07M
May 6, 2021
Q3
2020
Sep 30, 2019
$94.59M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$83.21M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$71.78M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$26.67M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$18.99M
May 8, 2025
Q3
2025
Sep 30, 2024
$32.77M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$33.39M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$16.56M
May 8, 2025
Q3
2024
Sep 30, 2023
($65.18M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
$1.11M
Aug 7, 2024
Q1
2024
Mar 31, 2023
($43.02M)
May 9, 2024
Q3
2023
Sep 30, 2022
($27.18M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($34.01M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($113.06M)
May 8, 2023
Q3
2022
Sep 30, 2021
($14.46M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($43.87M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($66.45M)
May 5, 2022
Q3
2021
Sep 30, 2020
($84.66M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($42.14M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($88.02M)
May 6, 2021
Q3
2020
Sep 30, 2019
($41.98M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($54.94M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$35.76M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$32.37M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$19.29M
May 8, 2025
Q3
2025
Sep 30, 2024
$31.64M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$30.44M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$15.21M
May 8, 2025
Q3
2024
Sep 30, 2023
($57.78M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
$3.04M
Aug 7, 2024
Q1
2024
Mar 31, 2023
($53.58M)
May 9, 2024
Q3
2023
Sep 30, 2022
($30.87M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($33.65M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($113.02M)
May 8, 2023
Q3
2022
Sep 30, 2021
($15.30M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($43.71M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($66.77M)
May 5, 2022
Q3
2021
Sep 30, 2020
($85.90M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($44.01M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($89.52M)
May 6, 2021
Q3
2020
Sep 30, 2019
($45.42M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($57.09M)
Aug 6, 2020